Essential thrombocytosis overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Essential ([[ET]]) or primary thrombocytosis is a rare hematologic disorder characterized by overproduction of platelets in the absence of an underlying disease. The disease, also called as Epstein-Goedel syndrome was first described by pathologists Emil Epstein and Alfred Goedel in the year 1934.<ref name="LevineGilliland2008">{{cite journal|last1=Levine|first1=R. L.|last2=Gilliland|first2=D. G.|title=Myeloproliferative disorders|journal=Blood|volume=112|issue=6|year=2008|pages=2190–2198|issn=0006-4971|doi=10.1182/blood-2008-03-077966}}</ref> Platelets are non-nucleated fragments of [[cytoplasm]] that aid in blood clotting by forming a [[platelet]] plug thus sealing off the site of injury in an effort to minimize or stop bleeding.<ref>Platelet. Wikipedia. https://en.wikipedia.org/wiki/Platelet Accessed on November 11, 2015.</ref> Normal platelet counts usually range from 150,000-450,000 platelets/μL of blood. [[Thrombocytosis]] is when the counts stay consistently higher at or more than 450,000 platelets/μL of blood and [[Thrombocytopenia]] is when the counts are consistently lower than 150,000 platelets/μL of blood. ET is grouped under the [[myeloproliferative]] disorders along with [[polycythemia vera]], [[chronic myeloid leukaemia]] and [[myelofibrosis]]. Rarely the disease progresses to [[acute myeloid leukemia]] (AML). The diagnosis of essential thrombocytosis is based on the [[WHO]] criteria, which include sustained elevation of platelet count >450,000/μL, [[bone marrow]] biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature [[megakaryocyte]]s; not meeting WHO criteria for [[polycythemia vera]], [[primary myelofibrosis]], BCR-ABL1–positive [[CML]], or [[myelodysplastic syndrome]], or other myeloid neoplasm; and demonstration of ''[[JAK2]] V617F'' or other clonal marker, or in the absence of ''JAK2 V617F'', no evidence of reactive thrombocytosis.<ref name="VardimanThiele2009">{{cite journal|last1=Vardiman|first1=J. W.|last2=Thiele|first2=J.|last3=Arber|first3=D. A.|last4=Brunning|first4=R. D.|last5=Borowitz|first5=M. J.|last6=Porwit|first6=A.|last7=Harris|first7=N. L.|last8=Le Beau|first8=M. M.|last9=Hellstrom-Lindberg|first9=E.|last10=Tefferi|first10=A.|last11=Bloomfield|first11=C. D.|title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes|journal=Blood|volume=114|issue=5|year=2009|pages=937–951|issn=0006-4971|doi=10.1182/blood-2009-03-209262}}</ref>
Essential ([[ET]]) or primary thrombocytosis is a rare hematologic disorder characterized by overproduction of platelets in the absence of an underlying disease. The disease, also called as Epstein-Goedel syndrome was first described by pathologists Emil Epstein and Alfred Goedel in the year 1934.<ref name="LevineGilliland2008">{{cite journal|last1=Levine|first1=R. L.|last2=Gilliland|first2=D. G.|title=Myeloproliferative disorders|journal=Blood|volume=112|issue=6|year=2008|pages=2190–2198|issn=0006-4971|doi=10.1182/blood-2008-03-077966}}</ref> Platelets are non-nucleated fragments of [[cytoplasm]] that aid in blood clotting by forming a [[platelet]] plug thus sealing off the site of injury in an effort to minimize or stop bleeding.<ref>Platelet. Wikipedia. https://en.wikipedia.org/wiki/Platelet Accessed on November 11, 2015.</ref> Normal platelet counts usually range from 150,000-450,000,000 ×10³ platelets/L of blood. [[Thrombocytosis]] is when the counts stay consistently higher at or more than 150,000-450,000,000 ×10³ platelets/L of blood and [[thrombocytopenia]] is when the counts are consistently lower than 150,000,000 ×10³ platelets/L of blood. Essential thrombocytosis is grouped under the [[myeloproliferative]] disorders along with [[polycythemia vera]], [[chronic myeloid leukaemia]] and [[myelofibrosis]]. Rarely the disease progresses to [[acute myeloid leukemia]] (AML). The diagnosis of essential thrombocytosis is based on the [[WHO]] criteria, which include sustained elevation of platelet count >450,000/μL, [[bone marrow]] biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature [[megakaryocyte]]s; not meeting WHO criteria for [[polycythemia vera]], [[primary myelofibrosis]], BCR-ABL1–positive [[CML]], or [[myelodysplastic syndrome]], or other myeloid neoplasm; and demonstration of ''[[JAK2]] V617F'' or other clonal marker, or in the absence of ''JAK2 V617F'', no evidence of reactive thrombocytosis.<ref name="VardimanThiele2009">{{cite journal|last1=Vardiman|first1=J. W.|last2=Thiele|first2=J.|last3=Arber|first3=D. A.|last4=Brunning|first4=R. D.|last5=Borowitz|first5=M. J.|last6=Porwit|first6=A.|last7=Harris|first7=N. L.|last8=Le Beau|first8=M. M.|last9=Hellstrom-Lindberg|first9=E.|last10=Tefferi|first10=A.|last11=Bloomfield|first11=C. D.|title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes|journal=Blood|volume=114|issue=5|year=2009|pages=937–951|issn=0006-4971|doi=10.1182/blood-2009-03-209262}}</ref>


==References==
==References==

Revision as of 15:54, 17 November 2015

Essential thrombocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes

Differentiating Essential thrombocytosis from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Essential thrombocytosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Essential thrombocytosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Essential thrombocytosis overview

CDC on Essential thrombocytosis overview

Essential thrombocytosis overview in the news

Blogs on Essential thrombocytosis overview

Directions to Hospitals Treating Essential thrombocytosis

Risk calculators and risk factors for Essential thrombocytosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Overview

Essential (ET) or primary thrombocytosis is a rare hematologic disorder characterized by overproduction of platelets in the absence of an underlying disease. The disease, also called as Epstein-Goedel syndrome was first described by pathologists Emil Epstein and Alfred Goedel in the year 1934.[1] Platelets are non-nucleated fragments of cytoplasm that aid in blood clotting by forming a platelet plug thus sealing off the site of injury in an effort to minimize or stop bleeding.[2] Normal platelet counts usually range from 150,000-450,000,000 ×10³ platelets/L of blood. Thrombocytosis is when the counts stay consistently higher at or more than 150,000-450,000,000 ×10³ platelets/L of blood and thrombocytopenia is when the counts are consistently lower than 150,000,000 ×10³ platelets/L of blood. Essential thrombocytosis is grouped under the myeloproliferative disorders along with polycythemia vera, chronic myeloid leukaemia and myelofibrosis. Rarely the disease progresses to acute myeloid leukemia (AML). The diagnosis of essential thrombocytosis is based on the WHO criteria, which include sustained elevation of platelet count >450,000/μL, bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes; not meeting WHO criteria for polycythemia vera, primary myelofibrosis, BCR-ABL1–positive CML, or myelodysplastic syndrome, or other myeloid neoplasm; and demonstration of JAK2 V617F or other clonal marker, or in the absence of JAK2 V617F, no evidence of reactive thrombocytosis.[3]

References

  1. Levine, R. L.; Gilliland, D. G. (2008). "Myeloproliferative disorders". Blood. 112 (6): 2190–2198. doi:10.1182/blood-2008-03-077966. ISSN 0006-4971.
  2. Platelet. Wikipedia. https://en.wikipedia.org/wiki/Platelet Accessed on November 11, 2015.
  3. Vardiman, J. W.; Thiele, J.; Arber, D. A.; Brunning, R. D.; Borowitz, M. J.; Porwit, A.; Harris, N. L.; Le Beau, M. M.; Hellstrom-Lindberg, E.; Tefferi, A.; Bloomfield, C. D. (2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–951. doi:10.1182/blood-2009-03-209262. ISSN 0006-4971.


Template:WikiDoc Sources